. Food and Drug Administration. Psychopharmacologic Drugs Advisory Committee and the Anti-Infective Drugs Advisory Committee. Briefing information. February 2, 2004. www.fda.gov.ohrms/dockets/ac/04/briefing/4006b1.htm (accessed 2004Mar22).
3.
. TeicherMHGlodCColeJP.Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry1990;147:207–10.
4.
. HealyDWhitakerC.Antidepressants and suicide: risk—benefit conundrums. J Psychiatry Neurosci2003;28:331–7.
5.
. HealyDLangmaackCSavageM.Suicide in the course of the treatment of depression. J Psychopharmacol1999;13:94–9.
6.
. BeasleyCMDornseifBEBosomworthJCSaylerMERampeyAHJrHeiligensteinJHFluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ1991;303:685–92.
7.
. TollefsonGDFawcettJWinokurGBeasleyCMJrPotvinJHFariesDEEvaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. Ann Clin Psychiatry1993;5:209–24.
8.
. MontgomerySADunnerDLDunbarG.Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol1995;5:5–13.
9.
. WatersR.FDA was urged to limit kids' antidepressants. San Francisco Chronicle, April16, 2004:A1, A19.
10.
. MathewsAW.FDA revisits issue of antidepressants for youths; new analysis may pressure agency to set limit on use because of suicide risk. Wall Street Journal. August5, 2004:A1.
11.
. SokeroTPMelartinTKRytsalaHJLeskelaUSLestela-MielonenPSIsometsaET.Suicidal ideation and attempts among psychiatric patients with major depressive disorder. J Clin Psychiatry2003;64:1094–100.
12.
. MaloneKMHaasGLSweeneyJAMannJJ.Major depression and the risk of attempted suicide. J Affect Disord1995;34:173–85.
13.
. RhodesAELinksPS.Suicide and suicidal behaviours: implications for mental health services. Can J Psychiatry1998;43:785–91.
14.
. Practice guideline for major depressive disorder in adults. Washington, DC: American Psychiatric Association Press, 1993.
15.
. WalshMTDinanTG.Selective serotonin reuptake inhibitors and violence: review of the available evidence. Acta Psychiatr Scand2001;104:84–91.
16.
. OlfsonMMarcusSCDrussBElinsonLTanielianTPincusHA.National trends in the outpatient treatment of depression. JAMA2002;287:203–9.
. OquendoMAKamaliMEllisSPGrunebaumMFMaloneKMBrodskyBSAdequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry2002;159:1746–51.
19.
. OlfsonMGameroffMJMarcusSCWaslickBD.Outpatient treatment of child and adolescent depression in the United States. Arch Gen Psychiatry2003;60:1236–42.
. IsacssonGBergmanURichCL.Epidemiological data suggests antidepressants reduce suicide risk among depressives. J Affect Disord1996;41:1–8.
22.
. LeonACKellerMBWarshawMGMellerTISolomonDACoryellWProspective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry1999;156:195–201.
23.
. American College of Neuropsychopharmacology. Executive summary. Preliminary report of the task force on SSRIs and suicidal behavior. January 21, 2004. www.acnp.org/exec_summary (accessed 2004Mar22).
24.
. VitielloBSwedoS.Antidepressant medications in children. N Engl J Med2004;350:1489–91.
25.
. ZitoJMSaferDJDosReisSGardnerJFSoekenKBolesMRising prevalence of antidepressants among US youths. Pediatrics2002;109:721–7.
26.
. TunisSRStryerDBClancyCM.Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA2003;290:1624–32.
